- Home
- HLI vs QGEN Comparison
HLI vs QGEN Comparison
Compare HLI & QGEN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- HLI
- QGEN
- Stock Information
- Founded
- HLI 1972
- QGEN 1986
- Country
- HLI United States
- QGEN Netherlands
- Employees
- HLI N/A
- QGEN N/A
- Industry
- HLI Investment Managers
- QGEN Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- HLI Finance
- QGEN Health Care
- Exchange
- HLI Nasdaq
- QGEN Nasdaq
- Market Cap
- HLI 12.2B
- QGEN 9.9B
- IPO Year
- HLI 2015
- QGEN 1996
- Fundamental
- Price
- HLI $184.73
- QGEN $47.51
- Analyst Decision
- HLI Hold
- QGEN Buy
- Analyst Count
- HLI 6
- QGEN 8
- Target Price
- HLI $173.40
- QGEN $51.86
- AVG Volume (30 Days)
- HLI 397.0K
- QGEN 818.9K
- Earning Date
- HLI 01-28-2025
- QGEN 02-05-2025
- Dividend Yield
- HLI 1.24%
- QGEN 2.87%
- EPS Growth
- HLI 30.39
- QGEN N/A
- EPS
- HLI 4.89
- QGEN 0.41
- Revenue
- HLI $2,119,860,999.00
- QGEN $1,966,174,000.00
- Revenue This Year
- HLI $21.20
- QGEN $2.78
- Revenue Next Year
- HLI $15.73
- QGEN $5.45
- P/E Ratio
- HLI $37.73
- QGEN $110.95
- Revenue Growth
- HLI 18.82
- QGEN 0.62
- 52 Week Low
- HLI $119.28
- QGEN $39.03
- 52 Week High
- HLI $192.10
- QGEN $47.61
- Technical
- Relative Strength Index (RSI)
- HLI 63.06
- QGEN 69.65
- Support Level
- HLI $164.05
- QGEN $45.10
- Resistance Level
- HLI $174.42
- QGEN $46.26
- Average True Range (ATR)
- HLI 3.27
- QGEN 0.74
- MACD
- HLI 1.62
- QGEN 0.16
- Stochastic Oscillator
- HLI 99.18
- QGEN 96.98
About HLI Houlihan Lokey Inc.
Houlihan Lokey Inc is an investment bank with expertise in mergers and acquisitions, capital markets, financial restructuring, valuation, and strategic consulting. The firm serves corporations, institutions, and governments worldwide with offices in the United States, Europe, and the Asia-Pacific region. The company operates in three segments. In the Corporate Finance business segment, it provides M&A and capital markets advisory services. Through the Financial Restructuring business segment, the company advises on some of the complex restructurings around the world. Financial and Valuation Advisory Services business segment provides valuation and financial opinion, and financial and strategic consulting practices in the United States.
About QGEN Qiagen N.V.
Qiagen offers proprietary sample and assay technology to extract, purify, amplify, and interpret DNA, RNA, and proteins. The company's sales are split almost evenly between applications in life sciences and molecular diagnostics. Qiagen generates nearly 90% of its revenue from consumables with the balance coming from instrumentation and related services. The Americas account for the largest portion of the firm's revenue (52% of 2023 sales), followed by EMEA (32%), and the Asia-Pacific (16%).